ClinicalTrials.gg

Program

vorasidenib

Also written as “Vorasidenib”, “AG881” and “AG-881”.

Its studies are mostly in Astrocytoma · Glioma · Leukemia, Myeloid, Acute, led by 5 companies.

Furthest: phase 3, since Jul 6, 201512 company-led studies, 4 open or runningNext primary completion: Nov 23, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals50 open or runningphase 1since Jul 6, 2015Jul 6, 2015none ahead
Institut de Recherches Internationales Servier (I.R.I.S.)42 open or runningphase 2since Dec 10, 2025Nov 14, 2025Nov 23, 2026phase 1 · NCT07250633
Servier11 open or runningphase 3since Dec 24, 2024Dec 24, 2024none ahead
Servier (Tianjin) Pharmaceutical11 open or runningno phasesince Apr 29, 2025Apr 29, 2025Apr 2028NCT06969352
Servier Bio-Innovation10 open or runningphase 1since Apr 19, 2023Apr 19, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2015First study: phase 1 study in Leukemia, Myeloid, AcuteNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02492737 · 46 enrolled · United States, France
  2. May 21, 2019Phase 1 study in Healthy Male ParticipantsAgios Pharmaceuticals · NCT03960502 · 5 enrolled · United States
  3. Jul 3, 2019Phase 1 study in Healthy ParticipantsAgios Pharmaceuticals · NCT04015687 · 22 enrolled · United States
  4. Oct 4, 20192 phase 1 studies in Healthy VolunteersAgios Pharmaceuticals · NCT04128787, NCT04145128
  5. Apr 19, 2023Servier Bio-Innovation's first study: phase 1 study in Healthy SubjectsNew to Servier Bio-InnovationServier Bio-Innovation · NCT05843708 · 64 enrolled · United States
  6. Dec 24, 2024Servier's first study: phase 3 study in Residual or Recurrent Grade 2 IDH Mutant GliomaNew to ServierServier · NCT06780930 · 57 enrolled · China, Taiwan
  7. Apr 29, 2025Servier (Tianjin) Pharmaceutical's first study: no phase study in GliomaNew to Servier (Tianjin) PharmaceuticalServier (Tianjin) Pharmaceutical · NCT06969352 · 62 enrolled · China
  8. Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)'s first studies: 3 phase 1 studiesNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235774, NCT07235748, NCT07250633
  9. Dec 10, 2025Phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationPhase 2 reachedInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292 · 10 planned · United States, Australia, Canada

Ahead

  1. Nov 23, 2026Primary completion: phase 1 study in Severe Hepatic ImpairmentInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07250633
  2. Apr 2028Primary completion: no phase study in GliomaServier (Tianjin) Pharmaceutical · NCT06969352
  3. May 2, 2033Primary completion: phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292

TargetBeta

IDH1 →IDH2 →read by rule
“An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
“IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ranosidenibruleHUTCHMEDphase 37

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation · United States, Australia, Canada2RecruitingInstitut de Recherches Internationales Servier (I.R.I.S.)May 2, 203310
NCT07250633Severe Hepatic Impairment · United States1RecruitingInstitut de Recherches Internationales Servier (I.R.I.S.)Nov 23, 202620
NCT07235774Healthy Adult Female Participants · United Kingdom1CompletedInstitut de Recherches Internationales Servier (I.R.I.S.)Mar 13, 202628
NCT07235748Healthy Adult Participants · United Kingdom1CompletedInstitut de Recherches Internationales Servier (I.R.I.S.)Dec 23, 202528
NCT06969352Glioma · China–Active, not recruitingServier (Tianjin) PharmaceuticalApr 202862
NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma · China, Taiwan3Active, not recruitingServierMay 7, 202657
NCT05843708Healthy Subjects · United States1CompletedServier Bio-InnovationJul 28, 202364
NCT04145128Healthy Volunteers · United States1CompletedAgios PharmaceuticalsDec 11, 201932
NCT04128787Healthy Volunteers · United States1CompletedAgios PharmaceuticalsDec 18, 201936
NCT04015687Healthy Participants · United States1CompletedAgios PharmaceuticalsOct 9, 201922
NCT03960502Healthy Male Participants · United States1CompletedAgios PharmaceuticalsSep 7, 20195
NCT02492737Leukemia, Myeloid, Acute · United States, France1CompletedAgios PharmaceuticalsMar 21, 201846

How it is read

Names in the registry

  • “Vorasidenib”, 5 entries
  • “AG881”, 2 entries
  • “AG-881”, 2 entries
  • “Vorasidenib 20mg”, 1 entry
  • “Vorasidenib 40 mg Oral Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.